Background: Melan-A/MART-1 is a melanocytic differentiation marker recognized as an antigen on melanoma cells. It is a useful diagnostic marker for pathologists in the diagnosis of melanocytic tumors. However, we recently found that Melan-A can be expressed in some non-melanocytic carcinomas that are rarely reported in the literature.
Methods: We analyzed the expression of Melan-A in 87 non-melanocytic carcinoma tissue samples by immunohistochemistry. Marker positivity was defined as ≥10% positive tumor cells.
Results: In 87 non-melanocytic carcinoma tissue samples, Melan-A was positive in six (6.89%) cases, of which four (66.7%) were male and two (33.3%) were female, with a mean age of 60 years (range 21-82 years). Five (83.3%) of the Melan-A-positive cases had distant metastases. Compared with Melan-A negative cases, Melan-A positive non-melanocytic carcinomas were significantly associated with poor prognosis (=0.0023).
Conclusions: Melan-A expression is relatively rare in non-melanocytic carcinoma cases. This report highlights a potential diagnostic pitfall in the diagnosis of melanoma, urges pathologists to exercise caution in cases of Melan-A positivity, and illustrates the need for an immunohistochemical marker panel to avoid misdiagnosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.14670/HH-18-696 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeted Drug Delivery in Periorbital Non-Melanocytic Skin Malignancies.
Bioengineering (Basel)
October 2024
Department of Ophthalmology, University Hospital of Udine, p.le S. Maria della Misericordia 15, 33100 Udine, Italy.
Targeted drug delivery has emerged as a transformative approach in the treatment of periorbital skin malignancies, offering the potential for enhanced efficacy and reduced side effects compared to traditional therapies. This review provides a comprehensive overview of targeted therapies in the context of periorbital malignancies, including basal cell carcinoma, squamous cell carcinoma, sebaceous gland carcinoma, and Merkel cell carcinoma. It explores the mechanisms of action for various targeted therapies, such as monoclonal antibodies, small molecule inhibitors, and immunotherapies, and their applications in treating these malignancies.
View Article and Find Full Text PDFTranscriptomic analysis of genes associated with vitamin D receptor signalling reveals differences between skin cancers.
Exp Dermatol
October 2024
Department of Pathology, São Paulo State University-UNESP, Botucatu, São Paulo, Brazil.
Vitamin D activates the vitamin D receptor (VDR), which dimerizes preferentially with the retinoid X receptor-α (RXRα). This heterodimer connects with genetic elements responsive to vitamin D, inhibiting or stimulating gene activity. We performed Nanostring® analysis of VDR/RXRα to compare the mRNA expression of this heterodimer and their correlated transcriptomes in non-melanoma skin cancer (basal cell carcinomas (BCC) and squamous cell carcinomas (SCC)) and melanocytic lesions (intradermal nevi (IN), and melanomas (MM)) with control skin.
View Article and Find Full Text PDFMore than one shade of pink as a marker of early amelanotic/hypomelanotic melanoma.
J Dermatol
July 2024
Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
Article Synopsis
- * The study analyzed 133 digital images of skin lesions diagnosed as either early amelanotic melanoma or non-melanocytic lesions, using assessments by three blinded dermatologists.
- * Results indicated specific features in lesions (like multiple shades of pink and irregular dots) can significantly increase the likelihood of accurate diagnosis of early amelanotic melanoma compared to non-melanoma lesions.
Melanoma is the most common malignant oral tumor in dogs. It frequently presents a diagnostic challenge as many melanomas lack or contain scant melanin and may have a variable microscopic phenotype. Previous studies evaluating immunohistochemical markers for diagnosing melanoma have shown limited sensitivity and/or specificity for S-100, PNL2, melan A, TRP-1, TRP-2, and HMB-45.
View Article and Find Full Text PDFMinimally Invasive Plasma Device Management of Multiple Benign Skin Cancers Associated with Rare Genodermatoses-Case Series and Review of the Therapeutic Methods.
J Clin Med
July 2024
Department of Dermatology, Military Institute of Medicine-National Research Institute, Central Clinical Hospital Ministry of Defense, Szaserow 128, 04-141 Warsaw, Poland.
Article Synopsis
- * A recent study looked at 11 patients with skin tumors, showing that a new FDA-approved plasma device was very effective for treating some of them, leading to great results.
- * Having multiple skin tumors, especially on the face, can be tough for people's feelings and lives, so finding the right treatment that works for each person is really important.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!